Top Markets
#1 Electroneum Electroneum +15.55%
#2 Status Status +13.74%
#3 Infinity Ground Infinity Ground +11.65%
#4 Ski Mask Dog Ski Mask Dog +8.30%
#5 City Boy City Boy +7.12%
#6 TG.Casino TG.Casino +6.50%
#7 Thena Thena +5.32%
#8 Akash Network Akash Network +4.79%
#9 The Grays Currency The Grays Currency +4.63%
#10 Bitway Bitway +4.58%
Coin of the day
Electroneum Electroneum
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated

VRTX
Rangering i aksjer #171
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in... Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Aksjekurs
$451.59
Markedsverdi
$114.70B
Endring (1 dag)
-2.36%
Endring (1 år)
-11.89%
Land
US
Handel Vertex Pharmaceuticals Incorporated (VRTX)

Kategori

Healthcare
Antall utestående aksjer for Vertex Pharmaceuticals Incorporated (VRTX)
Antall utestående aksjer per December 2025: 253.90M
Ifølge Vertex Pharmaceuticals Incorporated sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 253.90M. Ved slutten av December 2024 hadde selskapet 257.50M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Vertex Pharmaceuticals Incorporated (VRTX) fra 2000 til 2026
Utestående aksjer ved utgangen av hvert år
År Utestående aksjer Endre
2026 (TTM) 253.90M -0.70%
2025 255.70M -0.70%
2024 257.50M -0.08%
2023 257.70M 0.62%
2022 256.10M -0.62%
2021 257.70M -0.82%
2020 259.84M 1.21%
2019 256.73M 0.96%
2018 254.29M 2.18%
2017 248.86M 2.16%
2016 243.59M 1.14%
2015 240.84M 2.52%
2014 234.92M 4.49%
2013 224.83M 6.08%
2012 211.95M 3.44%
2011 204.89M 2.24%
2010 200.40M 15.67%
2009 173.26M 23.27%
2008 140.56M 8.97%
2007 128.99M 13.92%
2006 113.22M 26.87%
2005 89.24M 13.58%
2004 78.57M 2.03%
2003 77.00M 1.66%
2002 75.75M 1.73%
2001 74.46M 10.02%
2000 67.68M 0.00%
Utestående aksjer for lignende selskaper eller konkurrenter
Selskap Utestående aksjer Forskjell Land
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 4.45B 1,651.81%
DK
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 102.90M -59.47%
US
UCB SA UCB SA
UCB SA
UCB.BR
 190.00M -25.17%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 483.58M 90.46%
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 61.42M -75.81%
NL